Researchers sought to determine whether a real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with ALL.

Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study ...

Glucarpidase treatment significantly improves kidney recovery odds and reduces risks of neutropenia and transaminitis in MTX-AKI patients. The study utilized a target trial emulation framework to ...

THURSDAY, Jan. 16, 2025 (HealthDay News) -- For patients with methotrexate (MTX)-acute kidney injury (AKI), glucarpidase is associated with improved renal and extrarenal outcomes, according to a ...

Glucarpidase receipt within 4 days of MTX initiation was significantly associated with 2.7-fold increased odds of kidney recovery without dialysis dependence at hospital discharge compared with ...

TOPLINE: Glucarpidase treatment in patients with methotrexate-associated acute kidney injury is linked to 2.7 times higher odds of kidney recovery and faster recovery time. The enzyme also reduces ...

Glucarpidase converts MTX in the blood into inactive metabolites within 15 minutes of its administration. Despite its potent biochemical effects, no study has examined whether these effects ...

Treatment with glucarpidase was associated with a 2.7-fold increase in the odds of kidney recovery compared with no glucarpidase treatment (adjusted OR 2.70, 95% CI 1.69-4.31) in data from ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data ...

An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by ...

Glucarpidase Injection(Voraxaze) generic is a carboxypeptidase enzyme, prescribed for reducing methotrexate toxic level in kidney failure patients. It converts methotrexate into an inactive substance.